Serine peptide phosphoester prodrugs of cyclic cidofovir: Synthesis, transport, and antiviral activity

Molecular Pharmaceutics

Volumn 5, Issue 4, 2008, Pages 598-609

  Eriksson, Ulrika ^a,b   Peterson, Larryn W ^a   Kashemirov, Boris A ^a   Hilfinger, John M ^c   Drach, John C ^b   Borysko, Katherine Z ^b   Breitenbach, Julie M ^b   Kim, Jae Seung ^c   Mitchell, Stefanie ^c   Kijek, Paul ^c   McKenna, Charles E ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c TSRL INC   (United States)

Author keywords

Antiviral activity; Cyclis cidofovir; Drug delivery; Oral bioavailability; Prodrug

Indexed keywords

2 (2 AMINO 3 METHYL BUTYRYLAMINO) 3 [5 (4 AMINO 2 OXO 2H PYRIMIDIN 1 YLMETHYL) 2 OXIDO 1,4,2 DIOXAPHOSPHINAN 2 YLOXY]PROPANOIC ACID METHYL ESTER; 2 (2 AMINO 4 METHYL PENTANOYLAMINO) 3 [5 (4 AMINO 2 OXO 2H PYRIMIDIN 1 YLMETHYL) 2 OXIDO 1,4,2 DIOXAPHOSPHINAN 2 YLOXY]PROPANOIC ACID METHYL ESTER; 2 ACETYLPYRIDINE THIOSEMICARBAZONE; 3 [5 (4 AMINO 2 OXO 2H PYRIMIDIN 1 YL METHYL) 2 OXIDO 1,4,2 DIOXAPHOSPHINAN 2 YLOXY] 2 (2 AMINO 3 PHENYL PROPIONYLAMINO)PROPANOIC ACID METHYL ESTER; 3 [5 (4 AMINO 2 OXO 2H PYRIMIDIN 1 YL METHYL) 2 OXIDO 1,4,2 DIOXAPHOSPHINAN 2 YLOXY] 2 (2 AMINO PROPIONYLAMINO)PROPANOIC ACID METHYL ESTER; CIDOFOVIR; GANCICLOVIR; PRODRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; CANCER CELL CULTURE; CELL STRAIN CACO 2; CHEMICAL MODIFICATION; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTROLLED STUDY; COWPOX VIRUS; CYTOMEGALOVIRUS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG PENETRATION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TRANSPORT; DRUG UPTAKE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; ORTHOPOXVIRUS; PRIORITY JOURNAL; RAT; REACTION ANALYSIS; SKIN FIBROBLAST; STRUCTURE ACTIVITY RELATION; TISSUE HOMOGENATE; VACCINIA VIRUS;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE, TUMOR; CYTOMEGALOVIRUS; CYTOSINE; ELECTROSTATICS; ESTERIFICATION; HUMANS; HYDROLYSIS; INTESTINES; MALE; MICE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PEPTIDES; PHOSPHONIC ACIDS; PRODRUGS; RATS; SERINE;

EID: 51049110960     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp8000099     Document Type: Conference Paper

References (53)

1. Holy, A.; Votruba, I.; Merta, A.; Cerny, J.; Vesely, J.; Vlach, J.; Sediva, K.; Rosenberg, I.; Otmar, M.; et al. Acyclic nucleotide analogs: synthesis, antiviral activity and inhibitory effects on some cellular and virus-encoded enzymes in vitro. Antiviral Res. 1990, 13 (6), 295-311.
2. De Clercq, E.; Holy, A. Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nat. Rev. Drug Discovery 2005, 4, 928-40.
3. De Clercq, E. In search of a selective antiviral chemotherapy. Clin. Microbiol. Rev. 1997, 10 (4), 674-93.
4. De Clercq, E. Cidofovir in the treatment of poxvirus infections. Antiviral Res. 2002, 55 (1), 1-13.
5. Henderson, D. A.; Inglesby, T. V.; Bartlett, J. G.; Ascher, M. S.; Eitzen, E.; Jahrling, P. B.; Hauer, J.; Layton, M.; McDade, J.; Osterholm, M. T.; O'Toole, T.; Parker, G.; Perl, T.; Russell, P. K.; Tonat, K. Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. J. Am. Med. Assoc. 1999, 281 (22), 2127-37.
6. De Clercq, E.; Neyts, J. Therapeutic potential of nucleoside/nucleotide analogues against poxvirus infections. Rev. Med. Virol. 2004, 14 (5), 289-300.
7. Kern, E. R. In vitro activity of potential anti-poxvirus agents. Antiviral Res. 2003, 57 (1-2), 35-40.
8. Quenelle Debra, C.; Collins Deborah, J.; Kern Earl, R. Efficacy of multiple- or single-dose cidofovir against vaccinia and cowpox virus infections in mice. Antimicrob. Agents Chemother. 2003, 47 (10), 3275-80.
9. Snoeck, R.; Holy, A.; Dewolf-Peeters, C.; Van Den Oord, J.; De Clercq, E.; Andrei, G. Antivaccinia activities of acyclic nucleoside phosphonate derivatives in epithelial cells and organotypic cultures. Antimicrob. Agents Chemother. 2002, 46 (11), 3356-61.
10. Cundy, K. C.; Li, Z. H.; Hitchcock, M. J.; Lee, W. A. Pharmacokinetics of cidofovir in monkeys. Evidence for a prolonged elimination phase representing phosphorylated drug. Drug Metab. Dispos. 1996, 24 (7), 738-44.
11. Wachsman, M.; Petty, B. G.; Cundy, K. C.; Jaffe, H. S.; Fisher, P. E.; Pastelak, A.; Lietman, P. S. Pharmacokinetics, safety and bioavailability of HPMPC (cidofovir) in human immunodeficiency virus-infected subjects. Antiviral Res. 1996, 29 (2,3), 153-61.
12. Cundy, K. C. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin. Pharmacokinet. 1999, 36 (2), 127-43.
13. Cundy, K. C.; Bidgood, A. M.; Lynch, G.; Shaw, J. P.; Griffin, L.; Lee, W. A. Pharmacokinetics, bioavailability, metabolism, and tissue distribution of cidofovir (HPMPC) and cyclic HPMPC in rats. Drug Metab. Dispos. 1996, 24 (7), 745-52.
14. Oliyai, R.; Arimilli, M. N.; Jones, R. J.; Lee, W. A. Pharmacokinetics of salicylate ester prodrugs of cyclic HPMPC in dogs. Nucleosides, Nucleotides Nucleic Acids 2001, 20 (4-7), 1411-4.
15. Beadle, J., R.; Hartline, C.; Aldern; Kathy, A.; Rodriguez, N.; Harden, E.; Kern, Earl, R.; Hostetler, Karl, Y. Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro. Antimicrob. Agents Chemother. 2002, 46 (8), 2381-6.
16. Lebeau, L; Andrei, G.; Dal Pozzo, F.; Beadle, J. R.; Hostetler, K. Y.; De Clercq, E.; van den Oord, J.; Snoeck, R. Activities of alkoxyalkyl esters of cidofovir (CDV), cyclic CDV, and (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine against orthopoxviruses in cell monolayers and in organotypic cultures. Antimicrob. Agents Chemother. 2006, 50 (7), 2525-9.
17. Holy, A. Phosphonomethoxyalkyl analogs of nucleotides. Curr. Pharm. Des. 2003, 9 (31), 2567-92.
18. Lee, W. A.; Martin, J. C. Perspectives on the development of acyclic nucleotide analogs as antiviral drugs. Antiviral Res. 2006, 71 (2-3), 254-9.
19. Ballatore, C.; McGuigan, C.; De Clercq, E.; Balzarini, J. Synthesis and evaluation of novel amidate prodrugs of PMEA and PMPA. Bioorg. Med. Chem. Lett. 2001, 11 (8), 1053-6.
20. Meier, C.; Balzarini, J. Application of the cycloSal-prodrug approach for improving the biological potential of phosphorylated biomolecules. Antiviral Res. 2006, 71 (2-3), 282-92.
21. Hartline, C. B.; Gustin, K. M.; Wan, W. B.; Ciesla, S. L.; Beadle, J. R.; Hostetler, K. Y.; Kern, E. R. Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: Activity against adenovirus replication in vitro. J. Infect. Dis. 2005, 191 (3), 396-9.
22. Buller, R. M.; Owens, G.; Schriewer, J.; Melman, L.; Beadle, J. R.; Hostetler, K. Y. Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model. Virology 2004, 318 (2), 474-81.
23. Bischofberger, N.; Hitchcock, M. J. M.; Chen, M. S.; Barkhimer, D. B.; Cundy, K. C.; Kent, K. M.; Lacy, S. A.; Lee, W. A.; Li, Z.-H.; et al. 1-[((S)-2-Hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl]cytosine, an intracellular prodrug for (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine with improved therapeutic index in vivo. Antimicrob. Agents Chemother. 1994, 38 (10), 2387-91.
24. Mendel, D. B.; Cihlar, T.; Moon, K.; Chen, M. S. Conversion of 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl] cytosine to cidofovir by an intracellular cyclic CMP phosphodiesterase. Antimicrob. Agents Chemother. 1997, 41 (3), 641-6.
25. Lalezari, J. P.; Stagg, R. J.; Kuppermann, B. D.; Holland, G. N.; Kramer, F.; Ives, D. V.; Youle, M.; Robinson, M. R.; Drew, W. L.; Jaffe, H. S. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial. Ann. Intern. Med. 1997, 126 (4), 257-263.
26. Eriksson, U.; Hilfinger, J. M.; Kim, J.-S.; Mitchell, S.; Kijek, P.; Borysko, K. Z.; Breitenbach, J. M.; Drach, J. C.; Kashemirov, B. A.; McKenna, C. E. Synthesis and biological activation of an ethylene glycol-linked amino acid conjugate of cyclic cidofovir. Bioorg. Med. Chem. Lett. 2007, 17 (3), 583-6.
27. Eriksson, U.; Peterson, L. W.; Kim, J.-S.; Mitchell, S.; Kijek, P.; Hilfinger, J. M.; Drach, J. C.; Kashemirov, B. A.; McKenna, C. E. Ethylene glycol-linked amino acid conjugates of cyclic cidofovir: synthesis and biological activity. Antiviral Res. 2006, 70 (1), A58.
28. McKenna, C. E.; Kashemirov, B. A.; Eriksson, U.; Amidon, G. L.; Kish, P. E.; Mitchell, S.; Kim, J.-S.; Hilfinger, J. M. Cidofovir peptide conjugates as prodrugs. J. Organomet. Chem. 2005, 690 (10), 2673-8.
29. Ferreira, P. M. T.; Maia, H. L. S.; Monteiro, L. S.; Sacramento, J. High yielding synthesis of dehydroamino acid and dehydropeptide derivatives. J. Chem. Soc., Perkin Trans. 1 1999, (24), 3697-703.
30. Paulitz, C.; Steglich, W. Stereoselective Modification of a Cyclopentapeptide via an alpha-(Ethylthio)glycine Residue. J. Org. Chem. 1997, 62 (24), 8474-8.
31. McKeever, B.; Pattenden, G. Total synthesis of trunkamide A, a novel thiazoline-based prenylated cyclopeptide metabolite from Lissoclinum sp. Tetrahedron 2003, 59 (15), 2713-27.
32. Brodfuehrer, P. R.; Howell, H. G.; Sapino, C., Jr.; Vemishetti, P. A practical synthesis of (S)-HPMPC. Tetrahedron Lett. 1994, 35, 3243-6.
33. Han, H.-K.; De Vrueh, R. L. A.; Rhie, J. K.; Covitz, K.-M. Y.; Smith, P. L.; Lee, C.-P.; Oh, D.-M.; Sadee, W.; Amidon, G. L. 5′-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm. Res. 1998, 15 (8), 1154-9.
34. Kim, J. S.; Mitchell, S.; Kijek, P.; Tsume, Y.; Hilfinger, J. M.; Amidon, G. L. The suitability of an in situ perfusion model for permeability determinations: utility for BCS Class 1 biowaiver requests. Mol. Pharm. 2006, 3 (6), 686-94.
35. Li, L. Y.; Amidon, G. L.; Kim, J. S.; Heimbach, T.; Kesisoglou, F.; Topliss, J. T.; Fleisher, D. Intestinal metabolism promotes regional differences in apical uptake of indinavir: coupled effect of P-glycoprotein and cytochrome P450 3A on indinavir membrane permeability in rats. J. Pharmacol. Exp. Ther. 2002, 301 (2), 586-93.
36. Lipka, E.; Hilfinger, J. M.; Siersma, C. A.; Tsume, Y.; Crison, J. R.; Ridgewell, R. E.; Amidon, G. L. Evaluation of Imiquimod and analogs with respect to their oral delivery potential. Proc. Int. Symp. Controlled Release Bioact. Mater. 1997, 24, 337-8.
37. Lipka, E.; Lennernas, H.; Amidon, G. L. Interspecies correlation of permeability estimates: the feasibility of animal data for predicting oral absorption in humans. Pharm. Res. 1995, 12, S-311.
38. Amidon, G. L.; Sinko, P. J.; Fleisher, D. Estimating human oral fraction dose absorbed: A correlation using rat intestinal membrane permeability for passive and carrier-mediated compounds. Pharm. Res. 1988, 5 (10), 651-54.
39. Turk, S. R.; Shipman, C., Jr.; Nassiri, R.; Genzlinger, G.; Krawczyk, S. H.; Townsend, L. B.; Drach, J. C. Pyrrolo[2,3-d]pyrimidine nucleosides as inhibitors of human cytomegalovirus. Antimicrob. Agents Chemother. 1987, 31 (4), 544-50.
40. Prichard, M. N.; Turk, S. R.; Coleman, L. A.; Engelhardt, S. L; Shipman, C., Jr.; Drach, J. C. A microtiter virus yield reduction assay for the evaluation of antiviral compounds against human cytomegalovirus and herpes simplex virus. J. Virol. Methods 1990, 28 (1), 101-6.
41. Kern, E. R.; Hartline, C.; Harden, E.; Keith, K.; Rodriguez, N.; Beadle James, R.; Hostetler Karl, Y. Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir. Antimicrob. Agents Chemother. 2002, 46 (4), 991-5.
42. Goldstein, A. Biostatistics, an introductory text; Macmillan: New York, 1964; p 272.
43. Bronson, J. J.; Ferrara, L. M.; Howell, H. G.; Brodfuehrer, P. R.; Martin, J. C. A new synthesis of the potent and selective antiherpes virus agent (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. Nucleosides Nucleotides 1990, 9 (6), 745-69.
44. Bronson, J. J.; Ghazzouli, I.; Hitchcock, M. J. M.; Webb, R. R.; Martin, J. C. Synthesis and antiviral activity of the nucleotide analog (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cystosine. J. Med. Chem. 1989, 32 (7), 1457-63.
45. Webb, R. R.; Wos, J. A.; Bronson, J. J.; Martin, J. C. Synthesis of (S)-N1-(3-hydroxy-2-phosphonylmethoxy)propylcytosine, (S)-HPMPC. Tetrahedron Lett. 1988, 29 (43), 5475-8.
46. Holy, A.; Rosenberg, I. Phosphonylalkoxyalkyl and phosphonylalkyl derivatives of heterocyclic bases. Nucleosides Nucleotides 1989, 8 (5-6), 673-88.
47. Holy, A.; Rosenberg, I.; Dvorakova, H. Acyclic nucleotide analogs. VI. Synthesis of (3-hydroxy-2-phosphonylmethoxypropyl) derivatives of heterocyclic bases. Collect. Czech. Chem. Commun. 1989, 54 (9), 2470-501.
48. Vemishetti, P.; Brodfuehrer, P. R.; Howell, H. G.; Sapino, C., Jr. Preparation of hydroxyphosphonomethoxypropyl nucleosides, 91-US55789202511, 19910806, 1992.
49. Miyazawa, T.; Hiramatsu, S.; Tsuboi, Y.; Yamada, T.; Kuwata, S. Studies of unusual amino acids and their peptides. XVII. The synthesis of peptides containing N-carboxymethyl amino acids. II. Bull. Chem. Soc. Jpn. 1985, 58 (7), 1976-82.
50. Louie, M. S.; Chapman, H. An efficient process for the synthesis of cyclic HPMPC. Nucleosides, Nucleotides Nucleic Acids 2001, 20 (4-7), 1099-1102.
51. Lazarus, R. A.; Benkovic, P. A.; Benkovic, S. J. Mechanism of hydrolysis of phosphorylethanolamine diesters. Intramolecular nucleophilic amine participation. J. Chem. Soc., Perkin Trans. 2 1980, (2), 373-9.
52. Lazarus, R. A.; Benkovic, S. J. Mechanism of hydrolysis of phosphorylethanolamine triesters. Multiple catalytic effects of an intramolecular amino group. J. Am. Chem. Soc. 1979, 101 (15), 4300-12.
53. Keith, K. A.; Wan, W. B.; Ciesla, S. L.; Beadle, J. R.; Hostetler, K. Y.; Kern, E. R. Inhibitory activity of alkoxyalkyl and alkyl esters of cidofovir and cyclic cidofovir against orthopoxvirus replication in vitro. Antimicrob. Agents Chemother. 2004, 48 (5), 1869-71.